To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis
Christopher Hansung Ko, previously Senior Vice President of Samsung Strategic Business Development, has been named the CEO of Samsung Bioepis. The joint venture’s Board of Directors will consist of five directors and one auditor.
The strategic collaboration between Samsung Biologics and Biogen Idec will enable Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars.
Construction of Samsung Bioepis’ research and development center, located at Samsung Biologics’ site in Song-do Incheon, Korea, has started and will be completed by the end of the year.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
